A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease
Open Access
- 6 June 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (6) , 938
Abstract
Previous studies found that cilostazol has a favorable effect on glucose and lipid homeostasis, endothelial function, atherosclerosis, and vasculo-angiogenesis. However, it is poorly understood whether these effects can translate into better clinical outcomes. This study investigated the outcome effect of cilostazol in patients with coronary artery disease (CAD) or at a high risk of cardiovascular (CV) disease. We conducted a randomized, double-blind, placebo-controlled trial involving 266 patients who received cilostazol, 200 mg/day (n = 134) or placebo (n = 132). Pre-specified clinical endpoints including composite major adverse cardiovascular events (MACE) (CV death, non-fatal myocardial infarct, non-fatal stroke, hospitalization for heart failure, or unplanned coronary revascularization), the composite major coronary event (MCE) and major adverse CV and cerebrovascular event (MACCE), were prospectively assessed. The mean duration of follow-up was 2.9 years. Relative to placebo, cilostazol treatment had a borderline effect on risk reduction of MACE (hazard ratio [HR], 0.67; 95% confidence interval (CI), 0.34–1.33), whereas the beneficial effect in favor of cilostazol was significant in patients with diabetes mellitus or a history of percutaneous coronary intervention (p for interaction, 0.02 and 0.06, respectively). Use of cilostazol, significantly reduced the risk of MCE (HR, 0.38; 95% CI, 0.17–0.86) and MACCE (HR, 0.47; 95% CI, 0.23–0.96). A significantly lower risk of angina pectoris (HR, 0.38; 95% CI, 0.17–0.86) was also observed in the cilostazol group. After multi-variable adjustment, cilostazol treatment independently predicted a lower risk of MCE. In conclusion, these results suggest cilostazol may have beneficial effects in patients with CAD or at a high risk of CV disease.Keywords
Funding Information
- Ministry of Health and Welfare of Taiwan (MOHW107-TDU-B-211-123003, MOHW108-TDU-B-211-133003, MOST 106-2811-B-006-060, MOST 107-2314-B-006-076-MY2, MOST 107-2811-B-006-017, MOST 109-2314-B-006-069-MY3, NCKUH-10203022, NCKUEDA-10714)
- Ministry of Science and Technology (MOHW107-TDU-B-211-123003, MOHW108-TDU-B-211-133003, MOST 106-2811-B-006-060, MOST 107-2314-B-006-076-MY2, MOST 107-2811-B-006-017, MOST 109-2314-B-006-069-MY3, NCKUH-10203022, NCKUEDA-10714)
- National Cheng Kung University Hospital Research Grant (MOHW107-TDU-B-211-123003, MOHW108-TDU-B-211-133003, MOST 106-2811-B-006-060, MOST 107-2314-B-006-076-MY2, MOST 107-2811-B-006-017, MOST 109-2314-B-006-069-MY3, NCKUH-10203022, NCKUEDA-10714)
- National Cheng Kung University Collaborative Research Grant (MOHW107-TDU-B-211-123003, MOHW108-TDU-B-211-133003, MOST 106-2811-B-006-060, MOST 107-2314-B-006-076-MY2, MOST 107-2811-B-006-017, MOST 109-2314-B-006-069-MY3, NCKUH-10203022, NCKUEDA-10714)
This publication has 43 references indexed in Scilit:
- A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascadeClinical Science, 2012
- A Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary LesionsJACC, 2011
- The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes MellitusCirculation, 2010
- Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes MellitusJACC, 2008
- Randomized Comparison of Cilostazol vs Clopidogrel After Drug-Eluting Stenting in Diabetic Patients CIilostazol for Diabetic Patients in Drug-Eluting Stent (CIDES) TrialCirculation Journal, 2008
- Endothelial Nitric Oxide Synthase Uncoupling Impairs Endothelial Progenitor Cell Mobilization and Function in DiabetesDiabetes, 2007
- Endothelial progenitor cells in patients with essential hypertensionJournal Of Hypertension, 2007
- Coronary Stent Restenosis in Patients Treated With CilostazolCirculation, 2005
- Circulating Endothelial Progenitor Cells and Cardiovascular OutcomesNew England Journal of Medicine, 2005
- Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial StenosisStroke, 2005